Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | Ilze Štrumfa | - |
dc.contributor.author | Axel Fredrik Heldin | - |
dc.contributor.other | Ārvalstu studentu nodaļa | lv-LV |
dc.contributor.other | International Student Department | en-UK |
dc.date.accessioned | 2021-05-03T21:06:16Z | - |
dc.date.available | 2021-05-03T21:06:16Z | - |
dc.date.issued | 2021 | - |
dc.identifier.uri | https://dspace.rsu.lv/jspui/handle/123456789/4027 | - |
dc.description | Medicīna | lv-LV |
dc.description | Medicine | en-UK |
dc.description | Veselības aprūpe | lv-LV |
dc.description | Health Care | en-UK |
dc.description.abstract | Aktualitāte: Vēžu imūnhistoķīmiskais profils ir izrādījies jaunu neoadjuvantas terapijas potenciālo mērķu avots. Plaušu ne-sīkšūnu vēža (NSCLC) gadījumā viens no šiem mērķiem ir Programmed death-l (PD-1) / Programmed death-ligand 1 (PD-L1) ceļš. Šajā pētījumā mēs novērtējam PD-1 ekspresijas modeli audzēja un stromas mikrovides apstākļos pacientiem, kuriem diagnosticēta plaušu adenokarcinoma (AC) vai plaušu plakanšūnu karcinoma (SCC). Materiāls un metodes: PD-1 sadalījuma analīzei tika iekļauti un stratificēti ķirurģiskie audu materiāli no 318 pacientiem, 97 (30,5%) SCC un 221 (69,5%) AC, pamatojoties uz dzimumu, audzēja stadiju, darbības stāvokli (PS) un smēķēšanas vēsturi. PD-1 RNS sekvencēšanas dati tika korelēti ar PD-1 ekspresiju mikrovidē. Rezultāti: PD-1 ekspresija, pamatojoties tikai uz vēža tipu, bija: SCCstroma (7.5%, 3.0 – 12.5%), SCCtumor (1.0%, 0.0 – 3.0%) un ACstroma (5.7%, 1.0 – 12.5%), ACtumor (0.5%, 0.0 - 3.0%). Smēķējošiem SCC pacientiem stromā bija augstāka PD-1 ekspresija (7.5%, 3.0 – 12.5%), salīdzinot ar personām, kas nekad nebija smēķējušas. nesmēķētājiem (0.0%, 0.0 – 5.0%), p = 0,039. Smēķējošiem AC pacientiem statistiski palielinājās PD-1 ekspresija audzēja mikrovidē (1.0%, 0.0 – 3.1%), salīdzinot ar personām, kas nekad nebija smēķējušas (0.0%, 0.0 – 1.0%), p = 0,004. Attiecībā uz dzimumu, audzēja stadiju un PS PD-1 ekspresijas sadalījums bija statistiski vienāds. PD-1 RNA sekvencēšanas dati uzrādīja spēcīgāko pozitīvo korelāciju ar PD-1 ekspresiju audzēja mikro videi AC, salīdzinot ar SCC. Secinājums: PD-1 vairāk tika izteikts stromas mikrovidē abos vēža tipos, taču starp AC un SCC pacientiem PD-1 ekspresijā attiecīgajā mikrovidē nebija atšķirību. Smēķēšanas vēsture bija saistīta ar augstāku PD-1 ekspresiju, salīdzinot ar cilvēkiem, kuri nekda nebija smēķējuši. | lv-LV |
dc.description.abstract | Background: The immunohistochemical profile of cancers has proved to be a source of new potential targets for neoadjuvant therapy. One of those targets in Non-cell small lung cancer (NSCLC) is the Programmed death-l (PD-1)/Programmed death-ligand 1 (PD-L1) pathway. In this study, we evaluate the PD-1 expression pattern in the tumor- and stroma microenvironment in patients diagnosed with pulmonary adenocarcinoma (AC) or pulmonary squamous cell carcinoma (SCC). Material and methods: Surgical tissue material from 318 patients, 97 (30.5 %) SCC and 221 (69.5 %) AC, were included and stratified based on gender, tumor stage, performance status (PS) and smoking history for PD-1 distributional analysis. PD-1 RNA sequencing data were correlated with PD-1 expression in the microenvironment. Results: The PD-1 expression based solely on cancer type was: SCCstroma (7.5 %, 3.0 – 12.5%), SCCtumor (1.0%, 0.0 – 3.0%) and ACstroma (5.7%, 1.0 – 12.5%), ACtumor (0.5%, 0.0 – 3.0%). Smoking SCC-patients displayed a higher PD-1 expression in stroma (7.5%, 3.0 - 12.5%) compared with never-smokers (0.0%, 0.0 - 5.0%), p = 0.039. While smoking AC-patients had a statistically increased PD-1 expression in tumor microenvironment (1.0 %, 0.0 - 3.1%) compared to never smokers (0.0%, 0.0 - 1.0%), p = 0.004. Concerning gender, tumor stage and PS, the distribution of PD-1 expression were statistically the same. PD-1 RNA sequencing data showed the strongest positive correlation with PD-1 expression for tumor microenvironment in AC compared to SCC. Conclusion: PD-1 was expressed more in the stroma microenvironment in both cancer types but there was no difference in PD-1 expression in the respective microenvironment between AC and SCC patients. Smoking history was associated with a higher PD-1 expression compared to never smokers. | en-UK |
dc.language.iso | en-UK | - |
dc.publisher | Rīgas Stradiņa universitāte | lv-LV |
dc.publisher | Rīga Stradiņš University | en-UK |
dc.rights | info:eu-repo/semantics/restrictedAccess | - |
dc.subject | Plaušu ne-sīkšūnu vēža (NSCLC) | lv-LV |
dc.subject | plaušu adenokarcinoma (AC) | lv-LV |
dc.subject | plaušu plakanšūnu karcinoma (SCC) | lv-LV |
dc.subject | Programmed death-l (PD-1) | lv-LV |
dc.subject | audzēja un stromas mikrovides | lv-LV |
dc.subject | dzimums | lv-LV |
dc.subject | audzēja stadija | lv-LV |
dc.subject | darbības stāvokli (PS) un smēķēšanas vēsturi. | lv-LV |
dc.subject | Non-small cell lung cancer (NSCLC) | en-UK |
dc.subject | pulmonary adenocarcinoma (AC) | en-UK |
dc.subject | pulmonary squamous cell carcinoma (SCC) | en-UK |
dc.subject | Programmed death-l (PD-1) | en-UK |
dc.subject | tumor- and stroma microenvironment | en-UK |
dc.subject | gender | en-UK |
dc.subject | tumor stage | en-UK |
dc.subject | performance status (PS) and smoking history. | en-UK |
dc.title | PD-1 Expression in Non-small Cell Lung Cancer | en-UK |
dc.title.alternative | PD-1 ekspresija ne-sīkšūnu plaušu vēža audos | lv-LV |
dc.type | info:eu-repo/semantics/other | en-UK |
Appears in Collections: | Studējošo pētnieciskie darbi |
Files in This Item:
File | Size | Format | |
---|---|---|---|
Arvalstu_studentu_nodala_SSNMF_2021_Axel_Fredrik_Heldin_024370.pdf | 15.05 MB | Adobe PDF | View/Open Request a copy![]() |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.